Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
GlaxoSmithKline

GlaxoSmithKline, Siena, Italy
https://www.gsk.com/en-gb/responsibility/inside-the-gvgh/

GSK Strep A
VACCINE

Prevention of Group A Streptococcus

The GSK Vaccines Institute for Global Health (GVGH) is developing a new vaccine for the prevention of Group A Streptococcus (Strep A) infections, commonly known as Strep Throat, a major reason for antibiotic prescriptions and cause of immune-mediated diseases. Most healthy people who become infected with Strep A bacteria develop nothing more than Strep Throat (pharyngitis), an infection and inflammation of the pharynx, the membrane-lined cavity at the back of the throat. Yet Strep A can pose a more serious health threat, particularly to people with weakened immune systems, when the bacteria invade the bloodstream or deeper tissues to produce severe infections, such as sepsis, necrotizing fasciitis (flesh-eating disease), and toxic shock syndrome. Strep A also can trigger post-infectious immune-mediated rheumatic heart disease (RHD), a leading cause of death in the developing world. Up to 20,000 cases of invasive Strep A disease occur each year, according to US figures, from which more than 1,250 people die. Globally, Strep A has been reported to cause more than 500,000 annual deaths, of which 319,000 are due to RHD, mostly in populations from low- and middle-income countries (LMICs). The GSK vaccine aims to reduce the incidence and severity of Strep A infections and in doing so, reduce the global burden of associated autoimmune sequelae and RHD, as well as associated antibiotic prescriptions, which contribute to increased resistance.

Current Development Stage: Preclinical

CARB-X Investment: Initial investment of up to $8.2m, with potential option payments up to $4.2m.

Initial CARB-X Investment Date: October 1, 2020

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023